Clinical Trials Logo

Clinical Trial Summary

This study will observe the efficacy and toxicities of 3-dimensional printing noncoplanar template assisted CT guided radioactive iodine-125 seeds implantation in the treatment of patients with recurrent chest wall malignancies after external beam radiotherapy prospectively, and analyzes the influence of clinical and dosimetric factors on the outcomes.


Clinical Trial Description

Radioactive Iodine-125 seed brachytherapy is a conventional treatment in Peking University Third Hospital. Radioactive Iodine-125 seed brachytherapy is the implantation of Iodine-125 seed into tumors.The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. This study will enroll the patients with recurrent chest wall malignancies after external beam radiotherapy (primary or metastasis) who underwent CT-guided radioactive iodine-125 seed implantation assisted by 3D-printing template from 2019 to 2021. The investigators evaluate the dose that covers 90% target volume(D90) and other parameters after the implantation. The efficacy and adverse events will be observed. Local control(LC) time and overall survival(OS) time are evaluated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04077710
Study type Observational
Source Peking University Third Hospital
Contact Zhe Ji, M.D.
Phone 008618710002823
Email aschoff@163.com
Status Recruiting
Phase
Start date May 1, 2020
Completion date April 30, 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03971045 - Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer Phase 2
Recruiting NCT05369234 - Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis Phase 3
Recruiting NCT05057143 - 3D Printed Implants for the Defect Reconstruction in Patients With Chest Wall Tumors N/A